Aurinia rallies $25M for lupus nephritis drug
Aurinia was the subject of acquisition rumors in October. Two months later, it's flying solo with $25 million in new financing to power its Phase 3 trial for lupus nephritis.
Nephritis
Aurinia was the subject of acquisition rumors in October. Two months later, it's flying solo with $25 million in new financing to power its Phase 3 trial for lupus nephritis.